Nothing Special   »   [go: up one dir, main page]

UY35454A - Muteínas de interleucina-2 para la expansión de células t reguladoras - Google Patents

Muteínas de interleucina-2 para la expansión de células t reguladoras

Info

Publication number
UY35454A
UY35454A UY0001035454A UY35454A UY35454A UY 35454 A UY35454 A UY 35454A UY 0001035454 A UY0001035454 A UY 0001035454A UY 35454 A UY35454 A UY 35454A UY 35454 A UY35454 A UY 35454A
Authority
UY
Uruguay
Prior art keywords
muteins
cells
interleucine
regulating
expansion
Prior art date
Application number
UY0001035454A
Other languages
English (en)
Inventor
Li Li
Marc A Gavin
Kannan Gunasekaran
Joshua T Pearson
Karow Margaret
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY35454A publication Critical patent/UY35454A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se proporcionan muteínas de la IL-2 y moléculas de fusión Fc de muteína de la IL-2 que preferentemente se expanden y activan las células reguladoras T y son susceptibles a producción a gran escala. También se proporcionan en la presente moléculas de Fc de IgG1 humana que carecen de o con función efectora altamente reducida y alta estabilidad a pesar de la falta de glicosilación en N297. También, se proporcionan en la presente péptidos enlazadores que están glicosilados cuando se expresan en células de mamífero.
UY0001035454A 2013-03-14 2014-03-14 Muteínas de interleucina-2 para la expansión de células t reguladoras UY35454A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361784669P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
UY35454A true UY35454A (es) 2014-09-30

Family

ID=50680166

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035454A UY35454A (es) 2013-03-14 2014-03-14 Muteínas de interleucina-2 para la expansión de células t reguladoras

Country Status (40)

Country Link
US (8) US9580486B2 (es)
EP (2) EP2970441B1 (es)
JP (5) JP6480409B2 (es)
KR (4) KR102418771B1 (es)
CN (2) CN105358570B (es)
AP (1) AP2015008737A0 (es)
AR (1) AR095541A1 (es)
AU (2) AU2014236281B2 (es)
BR (1) BR112015022440B1 (es)
CA (3) CA3149348C (es)
CL (2) CL2015002686A1 (es)
CR (2) CR20200004A (es)
CY (2) CY1121767T1 (es)
DK (2) DK2970441T3 (es)
EA (2) EA034326B1 (es)
ES (2) ES2737598T3 (es)
HK (1) HK1220695A1 (es)
HR (2) HRP20190970T1 (es)
HU (2) HUE043488T2 (es)
IL (2) IL241349B (es)
JO (1) JO3796B1 (es)
LT (2) LT2970423T (es)
MA (2) MA38477B1 (es)
ME (2) ME03482B (es)
MX (2) MX366854B (es)
MY (2) MY172991A (es)
NZ (1) NZ751148A (es)
PE (1) PE20151763A1 (es)
PH (1) PH12015502051A1 (es)
PL (2) PL2970441T3 (es)
PT (2) PT2970441T (es)
RS (2) RS58791B1 (es)
SG (2) SG11201507574VA (es)
SI (2) SI2970423T1 (es)
TN (1) TN2015000416A1 (es)
TR (2) TR201910802T4 (es)
TW (3) TWI784288B (es)
UA (1) UA119140C2 (es)
UY (1) UY35454A (es)
WO (2) WO2014153063A1 (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20190202898A9 (en) * 2012-04-03 2019-07-04 Novelmed Therapeutics, Inc. AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
AU2013326932B2 (en) * 2012-10-04 2019-06-06 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
KR102215405B1 (ko) 2013-03-15 2021-02-10 암젠 인크 인간 pac1 항체
US11098099B2 (en) 2014-02-06 2021-08-24 Hoffmann-La Roche Inc. Interleukin-2 fusion proteins and uses thereof
JP6768633B2 (ja) * 2014-07-21 2020-10-14 デリニア， インコーポレイテッド 自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子
EA034925B1 (ru) 2014-08-11 2020-04-07 Делиниа, Инк. Модифицированные варианты il-2, которые селективно активируют регуляторные т-клетки, для лечения аутоиммунных заболеваний
TW201620938A (zh) 2014-09-15 2016-06-16 安美基公司 雙特異性抗cgrp受體/pac1受體抗原結合蛋白質及其用途
EP3233192B1 (en) 2014-12-15 2021-04-14 Washington University Compositions and methods for targeted cytokine delivery
MX2017012966A (es) 2015-04-10 2018-06-06 Amgen Inc Muteinas de interleuquina 2 para la expansion de celulas t regulatorias.
PE20180132A1 (es) * 2015-04-10 2018-01-18 Amgen Inc Muteinas de interleuquina 2 para la expansion de celulas t regulatorias
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EP3390447A1 (en) 2015-12-15 2018-10-24 Amgen Inc. Pacap antibodies and uses thereof
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
AU2017216230B2 (en) * 2016-02-03 2023-07-06 Amgen Inc. BCMA and CD3 bispecific T cell engaging antibody constructs
DK3411404T3 (da) * 2016-02-03 2023-01-30 Amgen Res Munich Gmbh Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner
EA039859B1 (ru) * 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
US11053293B2 (en) 2016-02-05 2021-07-06 Washington University Compositions and methods for targeted cytokine delivery
CN107287273B (zh) * 2016-03-31 2021-03-09 复旦大学附属妇产科医院 表达Tim-3的外周血NK细胞在制备自然流产生物标记物中的用途
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
JP7422480B2 (ja) * 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
WO2017220704A1 (en) 2016-06-22 2017-12-28 David Klatzmann Genetically modified t lymphocytes
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
KR101928981B1 (ko) * 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
AU2017359172A1 (en) 2016-11-08 2019-05-16 Delinia, Inc. IL-2 variants for the treatment of autoimmune diseases
US11384336B2 (en) 2016-12-07 2022-07-12 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory T cells
KR20190129077A (ko) 2017-03-15 2019-11-19 팬디온 테라퓨틱스, 인코포레이티드 표적화된 면역관용
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
EP3630163A4 (en) 2017-05-24 2021-06-09 Pandion Operations, Inc. TARGETED IMMUNTOLERANCE
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
CA3076630A1 (en) 2017-10-04 2019-04-11 Amgen Inc. Transthyretin immunoglobulin fusions
BR112020009920A2 (pt) 2017-11-21 2020-12-15 The Board Of Trustees Of The Leland Stanford Junior University Agonistas parciais de interleucina-2
KR102687035B1 (ko) * 2017-12-06 2024-07-22 팬디온 오퍼레이션스, 인코포레이티드 Il-2 뮤테인 및 그 용도
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3720871A4 (en) * 2017-12-06 2021-09-15 Pandion Operations, Inc. TARGETED IMMUNTOLERANCE
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN111655718A (zh) 2017-12-19 2020-09-11 Xencor股份有限公司 经过工程化的il-2 fc融合蛋白
EP3733693A4 (en) * 2017-12-27 2021-12-22 Kyowa Kirin Co., Ltd. IL-2 VARIANT
BR112020013621A2 (pt) 2018-01-12 2020-12-01 Amgen Inc. anticorpos contra pac1 e usos dos mesmos
AU2019215034C1 (en) 2018-02-01 2022-01-06 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
WO2019158764A1 (en) 2018-02-16 2019-08-22 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
CA3094112A1 (en) * 2018-03-28 2019-10-03 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
JP7268059B2 (ja) 2018-06-07 2023-05-02 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー アグリコシル化抗体生産用形質転換マウスおよびこれから生産されたアグリコシル化抗体の用途
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN112654633A (zh) 2018-06-22 2021-04-13 科优基因公司 基于细胞因子的可生物活化药物及其使用方法
AU2019299357A1 (en) 2018-07-02 2021-01-14 Amgen Inc. Anti-steap1 antigen-binding protein
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
US20210236599A1 (en) 2018-08-13 2021-08-05 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
KR20210087472A (ko) * 2018-11-01 2021-07-12 산동 뉴 타임 파마슈티칼 코., 리미티드. 이중 특이성 항체 및 그 용도
EP3920899A2 (en) 2019-02-08 2021-12-15 The UAB Research Foundation Immunotherapy for the treatment and prevention of inflammatory bowel disease
CA3129317A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
WO2020168059A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
EP3946424A1 (en) 2019-03-29 2022-02-09 Institut Curie Interleukin-2 variants with modified biological activity
CN111944036B (zh) * 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
EP3972992A4 (en) 2019-05-20 2023-07-19 Pandion Operations, Inc. ANTI-MADCAM IMMUNE TOLERANCE
CN114269784A (zh) 2019-06-07 2022-04-01 美国安进公司 具有选择性可切割接头的双特异性结合构建体
WO2021007150A1 (en) 2019-07-08 2021-01-14 Amgen Inc. Multispecific transthyretin immunoglobulin fusions
AU2020323893A1 (en) * 2019-07-26 2022-02-17 Visterra, Inc. Interleukin-2 agents and uses thereof
AR119769A1 (es) * 2019-08-13 2022-01-12 Amgen Inc Muteínas de interleucina-2 para la expansión de células t reguladoras
AU2020346580A1 (en) 2019-09-13 2022-03-31 Kyowa Kirin Co., Ltd. DcR3 variant
EP4063492A4 (en) * 2019-11-20 2024-01-17 GI Cell, Inc. MEDIUM COMPOSITION FOR CULTURE OF T CELLS AND METHOD FOR CULTURE OF T CELLS USING SAME
JP2023505102A (ja) * 2019-11-29 2023-02-08 エヌケーマックス カンパニー リミテッド ナチュラルキラー細胞を製造する方法およびその組成物
US20230036793A1 (en) 2019-12-12 2023-02-02 Iltoo Pharma Interleukin 2 chimeric constructs
EP4077383A1 (en) 2019-12-17 2022-10-26 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
MX2022007754A (es) 2019-12-20 2022-07-19 Regeneron Pharma Nuevos agonistas de il2 y metodos de uso de estos.
IL294659A (en) 2020-01-14 2022-09-01 Synthekine Inc Methods and preparations of il2 skewed mutants
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations Inc TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
KR20220164569A (ko) * 2020-04-06 2022-12-13 렁 바이오테크놀로지 피비씨 모듈식 합성 수용체 및 사용 방법
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
CA3184351A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Bispecific binding constructs
WO2021253360A1 (en) * 2020-06-18 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
CN112048018B (zh) * 2020-08-31 2021-10-08 南方医科大学 一种嵌合t细胞生长因子及其应用
EP4236962A1 (en) 2020-10-29 2023-09-06 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
MX2023006573A (es) 2020-12-03 2023-06-19 Amgen Inc Constructos de inmunoglobulina con multiples dominios de union.
EP4255466A1 (en) * 2020-12-04 2023-10-11 Visterra, Inc. Methods of using interleukin-2 agents
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
US20230077531A1 (en) 2021-05-27 2023-03-16 Sanofi Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY
WO2023288283A2 (en) 2021-07-14 2023-01-19 Synthekine, Inc. Methods and compositions for use in cell therapy of neoplastic disease
JP2024530003A (ja) * 2021-08-06 2024-08-14 アムジエン・インコーポレーテツド 治療用タンパク質の単離
IL311883A (en) 2021-10-06 2024-06-01 Assist Publique H?Pitaux De Paris Interleukin 2 chimeric constructs with targeted specificity for inflammatory tissues
CA3234995A1 (en) * 2021-10-14 2023-04-20 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
IL312043A (en) 2021-10-14 2024-06-01 Teneobio Inc Mesothelin binding proteins and their uses
CA3238574A1 (en) * 2021-12-01 2023-06-08 Gregory Babcock Methods of using interleukin-2 agents
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
WO2023164476A2 (en) * 2022-02-22 2023-08-31 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disorders
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells
TW202413419A (zh) 2022-05-27 2024-04-01 法商賽諾菲公司 與ｎｋｐ４６和ｂｃｍａ變體結合之具有ｆｃ工程化的自然殺手（ｎｋ）細胞接合物
WO2024026358A1 (en) 2022-07-27 2024-02-01 Teneobio, Inc. Mesothelin binding proteins and uses thereof
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
TW202432574A (zh) 2022-10-25 2024-08-16 比利時商艾伯霖克斯公司 具有增強的效應子功能之糖基工程化Ｆｃ變體多肽
WO2024118771A1 (en) 2022-11-30 2024-06-06 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
WO2024151515A2 (en) 2023-01-09 2024-07-18 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2024178056A1 (en) 2023-02-21 2024-08-29 Teneobio, Inc. C-kit binding proteins, chimeric antigen receptors, and uses thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233A (en) 1837-06-14 Improvement in plows
US4447A (en) 1846-04-04 Car- wheel
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0351410A1 (en) 1987-03-18 1990-01-24 3i RESEARCH EXPLOITATION LIMITED Complement-binding peptide
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
CA2062582C (en) 1991-03-27 1996-03-26 Tse-Wen Chang Methods and substances for recruiting therapeutic agents to solid tissues
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
FR2752462B1 (fr) 1996-08-14 1998-10-23 Essilor Int Procede d'incorporation d'additifs dans un article ophtalmique au moyen d'un fluide a l'etat supercritique
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
AU762382B2 (en) 1998-09-29 2003-06-26 Pioneer Hi-Bred International, Inc. MAR/SAR elements flanking RSYN7-driven construct
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
ATE437891T1 (de) * 2000-12-07 2009-08-15 Lilly Co Eli Glp-1 fusionsproteine
US7259010B2 (en) 2000-12-15 2007-08-21 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region of interferon beta
ES2330201T3 (es) 2001-01-26 2009-12-07 Selexis S.A. Regiones de union a la matriz y metodos para el uso de las mismas.
JP4795640B2 (ja) 2001-12-04 2011-10-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 調節された選択性を有する免疫サイトカイン
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
BRPI0411132B8 (pt) * 2003-06-12 2021-05-25 Lilly Co Eli protéina de fusão heteróloga e seus usos
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
WO2005047512A2 (en) 2003-11-12 2005-05-26 Shering Corporation Plasmid system for multigene expression
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
RU2006135112A (ru) 2004-03-05 2008-04-10 Чирон Корпорейшн (Us) Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
CA2606809C (en) * 2005-05-06 2016-01-05 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
JP2009500458A (ja) * 2005-07-11 2009-01-08 マクロジェニクス，インコーポレーテッド ヒト化抗ｃｄ１６ａ抗体を用いる自己免疫疾患の治療方法
GB0623539D0 (en) 2006-11-24 2007-01-03 Avidex Ltd Polypeptides
CA2680792A1 (en) * 2007-03-15 2008-09-18 Biogen Idec Ma Inc. Treatment of autoimmune disorders
US20090016935A1 (en) 2007-07-09 2009-01-15 Andrianov Alexander K Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
CA2749539C (en) 2009-01-21 2022-07-19 Amgen Inc. Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases
EP2389192A4 (en) * 2009-01-23 2013-01-16 Biogen Idec Inc STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE
JP2013511281A (ja) 2009-11-23 2013-04-04 アムジェン インコーポレイテッド 単量体抗体Ｆｃ
JP2013514795A (ja) * 2009-12-22 2013-05-02 ノバルティス アーゲー 治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質
KR102099462B1 (ko) 2010-11-30 2020-04-10 제넨테크, 인크. 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도
AU2012215573B2 (en) * 2011-02-10 2015-11-26 Roche Glycart Ag Mutant interleukin-2 polypeptides
MX348071B (es) 2011-03-16 2017-05-26 Amgen Inc Variantes de fc.
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
ES2721882T3 (es) 2011-12-23 2019-08-06 Pfizer Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
WO2013177062A2 (en) 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
WO2014145016A2 (en) * 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
EA201591766A1 (ru) 2016-02-29
HRP20191075T1 (hr) 2019-09-20
ME03437B (me) 2020-01-20
CN105358570A (zh) 2016-02-24
SG11201507574VA (en) 2015-10-29
MX2015012890A (es) 2015-12-03
AU2014236316B2 (en) 2018-11-01
JP2023053148A (ja) 2023-04-12
EA201591731A1 (ru) 2016-04-29
PT2970441T (pt) 2019-06-11
WO2014153111A2 (en) 2014-09-25
MY172991A (en) 2019-12-17
TW202005979A (zh) 2020-02-01
PL2970441T3 (pl) 2019-09-30
EA032863B1 (ru) 2019-07-31
SI2970423T1 (sl) 2019-08-30
US20210094997A1 (en) 2021-04-01
PL2970423T3 (pl) 2019-10-31
KR20150130342A (ko) 2015-11-23
RS58854B1 (sr) 2019-07-31
KR102219124B1 (ko) 2021-02-22
AU2014236281B2 (en) 2018-03-08
BR112015022440B1 (pt) 2022-08-16
WO2014153111A3 (en) 2014-11-13
TWI784288B (zh) 2022-11-21
US10562950B2 (en) 2020-02-18
CY1121767T1 (el) 2020-07-31
EP2970423A2 (en) 2016-01-20
UA119140C2 (uk) 2019-05-10
AU2014236316A1 (en) 2015-10-08
TR201908362T4 (tr) 2019-06-21
EP2970423B1 (en) 2019-04-24
CA2906708A1 (en) 2014-09-25
JP2016514161A (ja) 2016-05-19
AR095541A1 (es) 2015-10-21
LT2970423T (lt) 2019-05-27
CR20150557A (es) 2015-11-10
TW202115106A (zh) 2021-04-16
JP6480409B2 (ja) 2019-03-13
HUE043488T2 (hu) 2019-08-28
JP2021040630A (ja) 2021-03-18
PT2970423T (pt) 2019-07-23
KR20230157526A (ko) 2023-11-16
PH12015502051B1 (en) 2016-01-18
HK1220695A1 (zh) 2017-05-12
LT2970441T (lt) 2019-06-10
US20140286898A1 (en) 2014-09-25
EP2970441A4 (en) 2016-11-23
KR102418771B1 (ko) 2022-07-08
JP2019058182A (ja) 2019-04-18
TN2015000416A1 (en) 2017-01-03
KR20220101009A (ko) 2022-07-18
CR20200004A (es) 2020-03-11
WO2014153063A1 (en) 2014-09-25
MY202248A (en) 2024-04-19
CN105143253B (zh) 2021-02-19
BR112015023145A2 (pt) 2017-11-21
IL241349B (en) 2018-08-30
MA38477A1 (fr) 2017-09-29
MX2015012912A (es) 2015-12-03
US9932380B2 (en) 2018-04-03
JP2016518823A (ja) 2016-06-30
CA2906708C (en) 2022-05-03
JP7227951B2 (ja) 2023-02-22
NZ712066A (en) 2021-05-28
DK2970441T3 (da) 2019-06-03
NZ751148A (en) 2021-05-28
SI2970441T1 (sl) 2019-07-31
CL2015002669A1 (es) 2016-09-09
TR201910802T4 (tr) 2019-08-21
US10829535B2 (en) 2020-11-10
MX366854B (es) 2019-07-26
EP2970441A1 (en) 2016-01-20
HUE044321T2 (hu) 2019-10-28
JO3796B1 (ar) 2021-01-31
TWI709572B (zh) 2020-11-11
US9580486B2 (en) 2017-02-28
JP6450365B2 (ja) 2019-01-09
TWI687435B (zh) 2020-03-11
ES2720225T3 (es) 2019-07-18
BR112015022440A2 (pt) 2017-10-24
MA49207B1 (fr) 2022-08-31
US11976102B2 (en) 2024-05-07
CN105358570B (zh) 2019-11-12
KR20150127185A (ko) 2015-11-16
AU2014236316A9 (en) 2018-11-08
US9546203B2 (en) 2017-01-17
HRP20190970T1 (hr) 2019-07-26
CA3149348C (en) 2023-09-12
IL241622B (en) 2020-09-30
ES2737598T3 (es) 2020-01-15
PE20151763A1 (es) 2015-12-10
ME03482B (me) 2020-01-20
SG11201507420UA (en) 2015-10-29
US20180319859A1 (en) 2018-11-08
US20140343252A1 (en) 2014-11-20
TW201522366A (zh) 2015-06-16
RS58791B1 (sr) 2019-07-31
CA2905141A1 (en) 2014-09-25
AU2014236281A1 (en) 2015-09-24
CA3149348A1 (en) 2014-09-25
US20180237489A1 (en) 2018-08-23
CY1121823T1 (el) 2020-07-31
EA034326B1 (ru) 2020-01-28
US20240327485A1 (en) 2024-10-03
MA49207A1 (fr) 2021-09-30
PH12015502051A1 (en) 2016-01-18
IL241349A0 (en) 2015-11-30
DK2970423T3 (da) 2019-07-08
MA38477B1 (fr) 2019-05-31
AP2015008737A0 (en) 2015-09-30
CN105143253A (zh) 2015-12-09
US20170081382A1 (en) 2017-03-23
EP2970441B1 (en) 2019-03-06
CL2015002686A1 (es) 2016-04-15
US20170137485A1 (en) 2017-05-18
US10093711B2 (en) 2018-10-09

Similar Documents

Publication Publication Date Title
UY35454A (es) Muteínas de interleucina-2 para la expansión de células t reguladoras
CO2017011487A2 (es) Muteínas de interleuquina 2 para la expansión de células t regulatorias
WO2016164937A3 (en) Interleukin-2 muteins for the expansion of t-regulatory cells
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
CO7121348A2 (es) Proteínas de fusión de interleuquina-2 y usos de las mismas
CR20140565A (es) Proteínas de fusión de interleuquina 10 y usos de las mismas
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
CR20230179A (es) PROTEÍNAS DE FUSIÓN FC HETERODIMÉRICAS IL 15/IL15Ra (Divisional 2019-0229)
WO2014100038A3 (en) Solar concentration system
MX2015014424A (es) Construcciones de proteinas mitocondriales y sus usos.
CL2017002553A1 (es) Muteínas de interleuquina 2 para la expansión de células t regulatorias
CL2024002155A1 (es) Muteínas de interleucina-2 para la expansión de células t reguladoras.
BR112014017788A2 (pt) proteína de fusão de interferona e de seção fc de imunoglobulina
MX2016009636A (es) Montaje de parasol con multiples espejos.
BR112013033562A2 (pt) proteína de fusão de tetranectina-apolipoproteína a-i encurtada, uma partícula de lipídio que a contém e uso das mesmas
BR112017003074A2 (pt) Célula isolada, e, métodos de produção de uma proteína recombinante de interesse e de glicosilação de um substrato de proteína de n- glicano.

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20231004